Better Therapeutics enters rebate pact with PBM for AspyreRx diabetes treatment

Better Therapeutics announced that it has entered into a rebate agreement with one of the nation’s leading Pharmacy Benefit Managers negotiating on behalf of over 70M lives in the US. The rebate agreement, effective January 1, 2024, applies to the PBM’s commercial book of business and provides plan participants of the PBM the ability to add AspyreRx to their formularies with rebate eligibility. Better Therapeutics launched AspyreRx in October 2023, after receiving U.S. FDA authorization in July 2023 as the first prescription-only digital therapeutic to treat adults with type 2 diabetes. The company continues to engage with national and regional health plans, as well as Pharmacy Benefit Managers and Group Purchasing Organizations, to communicate the value of AspyreRx for patients with T2D and to secure broad coverage.